IPP Bureau
Iconovo and Lonza to collaborate on formulation development of an intranasal biologic
By IPP Bureau - January 13, 2025
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Aragen secures $100 million investment from Quadria Capital
By IPP Bureau - January 13, 2025
Investment will fund expansion to meet rising demand for CRDMO services
Genome India Project marks a defining moment for country's biotechnology landscape: Modi
By IPP Bureau - January 11, 2025
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
By IPP Bureau - January 10, 2025
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology
By IPP Bureau - January 10, 2025
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Merieux completes acquisition of Bureau Veritas' food testing activities in Canada and US
By IPP Bureau - January 10, 2025
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe
By IPP Bureau - January 10, 2025
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Windlas Biotech’s new injectable facility receives GMP certification
By IPP Bureau - January 10, 2025
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Carbogen Amcis successfully completed Swissmedic inspection of its Vionnaz facility
By IPP Bureau - January 10, 2025
The site’s GMP Certification has been successfully renewed
PM Modi lays foundation stone of Kris City and bulk Drug Park at Nakkapalli
By IPP Bureau - January 09, 2025
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification
By IPP Bureau - January 09, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107
By IPP Bureau - January 09, 2025
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav
By IPP Bureau - January 09, 2025
Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors
JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
By IPP Bureau - January 09, 2025
He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
By IPP Bureau - January 09, 2025
Increases speed to market for drug developers working on nucleic acid therapeutics
